Biodexa Pharmaceuticals (BDRX) Accounts Payables (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Accounts Payables data on file, last reported at $3.4 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables fell 23.4% year-over-year to $3.4 million; the trailing twelve-month figure through Dec 2025 stood at $3.4 million (down 23.4% YoY), and the FY2025 full-year result was $3.4 million, down 24.07% from the prior year.
• Accounts Payables rose to $3.4 million in Q4 2025, from $1.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.5 million in Q4 2024 to a low of $1.5 million in Q4 2021.
• A 5-year average of $2.3 million and a median of $2.0 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables sank 43.41% in 2022 and soared 192.22% in 2024, its largest moves.
• Tracing BDRX's Accounts Payables over 5 years: stood at $1.5 million in 2021, then increased by 15.3% to $1.7 million in 2022, then retreated by 9.32% to $1.5 million in 2023, then soared by 192.22% to $4.5 million in 2024, then declined by 23.4% to $3.4 million in 2025.
• Business Quant data shows BDRX's Accounts Payables at $3.4 million in Q4 2025, $1.9 million in Q2 2025, and $4.5 million in Q4 2024.